BTK and B-cell chronic lymphocytic leukemia: On 28 February 2025, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for approval of pirtobrutinib for the treatment of patients with R/R CLL who have been previously treated with a BTK inhibitor [47].